共刺激受体:肿瘤免疫疗法的潜在靶点  

Co-stimulatory receptors:potential targets for tumor immunotherapy

作　　者：张伟明 孙坚萍(综述)[1] 赵艳(审校)[1] ZHANG Weiming;SUN Jianping;ZHAO Yan(Beijing You′An Hospital,Capital Medical University,Beijing 100071,China)

机构地区：[1]首都医科大学附属北京佑安医院,北京100071

出　　处：《实用肿瘤学杂志》2021年第5期441-446,共6页Practical Oncology Journal

基　　金：北京市医院管理局重点医学专业发展计划(编号:ZYLX201711);北京市医院管理局“登峰”人才培养计划(编号:DFL20181701);传染病相关疾病生物标志物北京市重点实验室(编号:BZ0373);首都卫生发展科研专项(编号:首发2020-1-2182)。

摘　　要：免疫细胞表面的共刺激受体对免疫细胞的活化、增殖及效应功能的发挥具有重要作用。在肿瘤中,共刺激受体经特异性激动性单克隆抗体激活后能增强免疫细胞的效应功能,促进对肿瘤细胞的杀伤,抑制肿瘤的生长,可作为抗肿瘤免疫疗法的靶点。本文就几种共刺激受体在生理条件下、肿瘤免疫及抗肿瘤免疫治疗中的作用进行了综述。Co-stimulatory receptors on the surface of immune cells play important role in the activation,proliferation and effectors′function of immune cells.In tumors,co-stimulatory receptors can be activated by specific agonistic monoclonal antibodies to enhance the effectors′function of immune cells,promote the killing of tumor cells,inhibit tumor growth,and can be used as a target for anti-tumor immunotherapy.This article reviews the role of several co-stimulatory receptors in the physiological conditions,tumor immunology and anti-tumor immunotherapy.

关 键 词：肿瘤 共刺激及抑制T细胞受体 免疫疗法 

分 类 号：R730.51[医药卫生—肿瘤]